Article
Urology & Nephrology
Staffan Jahnson, Peter Soderkvist, Firas Aljabery, Hans Olsson
Summary: In stage T1 urinary bladder cancer, the combination of TERT and p53 mutations is associated with tumor progression. A possible protective effect of the TERT promoter mutation against tumor progression induced by the p53 mutation and subsequent p53 accumulation in tumor cells may exist, but further investigations are necessary.
Article
Oncology
Omar Alhalabi, Andrew W. Hahn, Pavlos Msaouel, Alexander Y. Andreev-Drakhlin, Funda Meric-Bernstam, Aung Naing, Sarina Piha-Paul, Janku Filip, Shubham Pant, Timothy A. Yap, David S. Hong, Siqing Fu, Daniel Karp, Erick Campbell, Hung Le, Matthew T. Campbell, Amishi Y. Shah, Nizar M. Tannir, Arlene O. Siefker-Radtke, Jianjun Gao, Jason Roszik, Vivek Subbiah
Summary: The prognosis for patients with metastatic bladder carcinoma (mBC) remains limited, but experimental therapies such as FGFR inhibitors have shown potential efficacy in disease control. Analysis of genetic alterations in TP53, ERBB2, PI3KCA, FGFR3, and ARID1A could help in selecting treatment options for patients.
MOLECULAR CANCER RESEARCH
(2021)
Article
Oncology
Laura S. Mertens, Francesco Claps, Roman Mayr, Peter J. Bostrom, Shahrokh F. Shariat, Ellen C. Zwarthoff, Joost L. Boormans, Cheno Abas, Geert J. L. H. van Leenders, Stefanie Goetz, Katrin Hippe, Simone Bertz, Yann Neuzillet, Joyce Sanders, Annegien Broeks, Dennis Peters, Michiel S. van der Heijden, Michael A. S. Jewett, Robert Stoehr, Alexandre R. Zlotta, Markus Eckstein, Yanish Soorojebally, Deric K. E. van der Schoot, Bernd Wullich, Maximilian Burger, Wolfgang Otto, Francois Radvanyi, Nanour Sirab, Damien Pouessel, Theo H. van der Kwast, Arndt Hartmann, Yair Lotan, Yves Allory, Tahlita C. M. Zuiverloon, Bas W. G. van Rhijn
Summary: This study analyzed the expression of FGFR3 gene mutation, p53, and Ki-67 in patients with invasive bladder cancer and evaluated their prognostic value. The results showed that FGFR3 gene mutation was associated with lower tumor stage, lower tumor grade, no lymph node metastasis, and longer disease-specific survival. In contrast, abnormal expression of p53 and Ki-67 was only associated with higher tumor stage and G3 grade tumors. Multivariable analysis showed that besides tumor stage, lympho-vascular invasion, and lymph node stage, FGFR3 gene mutation status was a significant predictor of patient prognosis.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2022)
Article
Oncology
Andre L. De Souza, Anthony E. Mega, John Douglass, Adam J. Olszewski, Ece D. Gamsiz Uzun, Alper Uzun, Charissa Chou, Fenghai Duan, Jinyu Wang, Amin Ali, Dragan J. Golijanin, Sheldon L. Holder, Galina G. Lagos, Howard Safran, Wafik S. El-Deiry, Benedito A. Carneiro
Summary: Despite new therapies, advanced urothelial carcinoma still has a poor prognosis. FGFR2 and FGFR3 mutations, PD-L1 expression, tumor mutational burden, and microsatellite instability are predictive biomarkers. Novel biomarkers can improve treatment sequencing and outcomes.
AMERICAN JOURNAL OF CANCER RESEARCH
(2023)
Article
Pathology
Mariah Z. Leivo, David E. Tacha, Donna E. Hansel
Summary: This study examined the immunohistochemical expression of UPII and GATA-3 in a set of bladder cancer mimickers, finding weak immunoreactivity for UPII but greater and broader staining for GATA-3. Strong UPII immunoreactivity appeared to be specific for urothelial cell origin, while only one case showed dual positivity for UPII and GATA-3 in papillary nephrogenic adenoma.
Article
Urology & Nephrology
Gabriele Sorce, Rocco Simone Flammia, Benedikt Hoeh, Francesco Chierigo, Benedikt Horlemann, Christoph Wurnschimmel, Zhe Tian, Markus Graefen, Carlo Terrone, Michele Gallucci, Felix K. H. Chun, Fred Saad, Shahrokh F. Shariat, Francesco Montorsi, Alberto Briganti, Pierre Karakiewicz
Summary: Radical cystectomy reduces cancer-specific mortality in non-metastatic PCV bladder cancer patients, while chemotherapy does not improve outcomes in this group. Both chemotherapy and radical cystectomy lead to significantly lower cancer-specific mortality in metastatic PCV patients.
WORLD JOURNAL OF UROLOGY
(2022)
Article
Oncology
Nicholas H. Chakiryan, Da David Jiang, Kyle A. Gillis, Elizabeth Green, Ali Hajiran, Lee Hugar, Logan Zemp, Jingsong Zhang, Rohit Jain, Jad Chahoud, Roger Li, Wade Sexton, Brandon J. Manley, Scott M. Gilbert
Summary: This retrospective study compared the overall survival (OS) between first-line immunotherapy and chemotherapy in patients with metastatic bladder urothelial carcinoma. The findings suggest that there is no significant difference in OS between the two treatments.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2022)
Article
Oncology
Shengming Jin, Han Zeng, Zhaopei Liu, Kaifeng Jin, Chunnan Liu, Sen Yan, Yanze Yu, Runze You, Hongyi Zhang, Yuan Chang, Le Xu, Jiejie Xu, Zewei Wang, Yu Zhu
Summary: Stromal-infiltrating tumor-associated macrophages (TAMs) have clinical significance in muscle-invasive bladder cancer (MIBC), serving as a prognostic indicator and potentially guiding precise treatments.
ANNALS OF SURGICAL ONCOLOGY
(2022)
Article
Oncology
Sungmin Woo, Soleen Ghafoor, Jeeban P. Das, Natalie Gangai, Alvin C. Goh, Herbert Alberto Vargas
Summary: This study aimed to evaluate the MRI features of plasmacytoid urothelial carcinomas (PUC) of the bladder and their association with patient survival. The results showed that PUCs are typically large, diffuse tumors with features of extravesical extension (EVE) and pelvic peritoneal spread (PPS) on MRI, and these features are associated with survival.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2022)
Article
Oncology
Tiezhu Shi, Zhihao Yuan, Yanying He, Dongliang Zhang, Siteng Chen, Xiongjun Wang, Linli Yao, Jialiang Shao, Xiang Wang
Summary: The study reveals that p53 regulates serine metabolism in bladder cancer cells. TP53 gene mutation is positively correlated with PHGDH expression. WT p53 inhibits PHGDH expression by recruiting SIRT1 to the PHGDH promoter. Additionally, YY1 promotes PHGDH expression and promotes bladder tumorigenesis.
Article
Biochemistry & Molecular Biology
Ozge Saatci, Ozge Akbulut, Metin Cetin, Vitali Sikirzhytski, Meral Uner, Deniz Lengerli, Elizabeth C. C. O'Quinn, Martin J. J. Romeo, Burcu Caliskan, Erden Banoglu, Sercan Aksoy, Aysegul Uner, Ozgur Sahin
Summary: Centrosome amplification (CA) is a key characteristic of cancer, associated with aggressive disease and poor clinical outcomes. Transforming Acidic Coiled-Coil Containing Protein 3 (TACC3) is overexpressed in tumors with CA and plays a crucial role in ensuring proliferation and survival of cancer cells with CA. TACC3 forms distinct functional interactomes in mitosis and interphase, interacting with Kinesin Family Member C1 (KIFC1) and nucleosome remodeling and deacetylase (NuRD) complex to regulate mitotic progression and G1/S progression, respectively.
CELL DEATH AND DIFFERENTIATION
(2023)
Article
Oncology
Ambre Balestra, Denis Larsimont, Jean-Christophe Noel
Summary: Endometrial cancers with p53 mutations have a high risk of recurrence and metastasis. This study found that 31.4% of p53-mutated endometrial carcinomas overexpressed HER2, with 36.3% showing HER2 gene amplification. These findings suggest that anti-HER2 agents could be potential treatments for this type of cancer in the future.
Article
Multidisciplinary Sciences
Joshua Warrick, Wenhuo Hu, Hironobu Yamashita, Vonn Walter, Lauren Shuman, Jenna M. Craig, Lan L. Gellert, Mauro A. A. Castro, A. Gordon Robertson, Fengshen Kuo, Irina Ostrovnaya, Judy Sarungbam, Ying-bei Chen, Anuradha Gopalan, Sahussapont J. Sirintrapun, Samson W. Fine, Satish K. Tickoo, Kwanghee Kim, Jasmine Thomas, Nagar Karan, Sizhi Paul Gao, Timothy N. Clinton, Andrew T. Lenis, Timothy A. Chan, Zhiyu Chen, Manisha Rao, Travis J. Hollman, Yanyun Li, Nicholas D. Socci, Shweta Chavan, Agnes Viale, Neeman Mohibullah, Bernard H. Bochner, Eugene J. Pietzak, Min Yuen Teo, Gopa Iyer, Jonathan E. Rosenberg, Dean F. Bajorin, Matthew Kaag, Suzanne B. Merrill, Monika Joshi, Rosalyn Adam, John A. Taylor, Peter E. Clark, Jay D. Raman, Victor E. Reuter, Yu Chen, Samuel A. Funt, David B. Solit, David J. DeGraff, Hikmat A. Al-Ahmadie
Summary: Squamous differentiation in bladder cancer is associated with genomic and immunologic heterogeneity and resistance to immunotherapy. The loss of FOXA1, GATA3, and PPARG expression is involved in lineage plasticity and dysregulation of PD-L1 expression.
NATURE COMMUNICATIONS
(2022)
Article
Oncology
Yaxin Cheng, Yuxing Zhu, Mengqing Xiao, Yeyu Zhang, Zhanwang Wang, Haotian Chen, Ke Cao
Summary: This study reveals that circRNA_0067717 acts as a scaffold for TRIM41 and p53, promoting TRIM41-induced ubiquitination and degradation of p53, enhancing paclitaxel chemoresistance in NPC cells.
Article
Biochemistry & Molecular Biology
Mayao Luo, Yifan Zhang, Zhuofan Xu, Shidong Lv, Qiang Wei, Qiang Dang
Summary: The EP300-R1627W mutation plays a driver role in the development and progression of bladder cancer.
MOLECULAR MEDICINE
(2023)
Article
Cell Biology
Cecilia Taverna, Martina Baneckova, Monica Lorenzon, Annarita Palomba, Alessandro Franchi, Alena Skalova, Abbas Agaimy
Summary: Secretory carcinoma (SC) is a low-grade salivary gland tumor that shares morphological features with other salivary gland neoplasms, but MUC4 has been identified as a highly sensitive and specific marker for SC, which can be used to differentiate it from other tumors.
Article
Cell Biology
Cecilia Taverna, Federica Pollastri, Rudi Pecci, Beatrice Giannoni, Caterina Fattorini, Marco Santucci, Sarina K. Mueller, Robert Stoehr, Alessandro Franchi, Abbas Agaimy
Summary: Papillary neoplasms of the middle ear are rare and poorly characterised, often classified into aggressive papillary tumours (APTs) and endolymphatic sac tumours (ELSTs). This study presents two cases that do not fit into these categories, suggesting they represent a heterogeneous spectrum of distinct neoplasms. Further investigation is needed to determine the significance of the MKRN1-BRAF fusion in these cases.
Review
Biochemistry & Molecular Biology
Giacomo Casati, Laura Giunti, Anna Lisa Iorio, Arianna Marturano, Luisa Galli, Iacopo Sardi
Summary: Glioblastoma is a deadly tumor type with strong multidrug resistance and an immunosuppressive microenvironment. Understanding chemoresistance and immune response stimulation in GBM is crucial. The Hippo pathway plays a key role in these processes and is a promising target for treatment.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
Alessandro Ruggi, Fraia Melchionda, Iacopo Sardi, Rossana Pavone, Linda Meneghello, Lidija Kitanovski, Lorna Zadravec Zaletel, Paolo Farace, Mino Zucchelli, Mirko Scagnet, Francesco Toni, Roberto Righetto, Marco Cianchetti, Arcangelo Prete, Daniela Greto, Silvia Cammelli, Alessio Giuseppe Morganti, Barbara Rombi
Summary: Proton therapy shows favorable toxicity profile and promising results on late effects in children with medulloblastoma.
Editorial Material
Oncology
Asbiel Hasbum, Ozan Karabulut, Ruben Edgar Reyes, Claudio Ricci, Alessandro Franchi, Serena Danti, Sue Anne Chew
Summary: This commentary highlights the potential of using biomaterials combined with patient-derived cancer cells as a 3D in vitro model for cancer research and treatment. While this approach is relatively new and uncommon in clinics, studies have shown promising results in creating 3D models that mimic in vivo tumors. However, there are limitations and challenges, including the need for familiarity with biomaterial scaffolds and the development of easy-to-handle scaffolds for routine assessment.
Article
Oncology
Richard E. Kast, Alex Alfieri, Hazem Assi, Terry C. Burns, Ashraf M. Elyamany, Maria Gonzalez-Cao, Georg Karpel-Massler, Christine Marosi, Michael E. Salacz, Iacopo Sardi, Pieter Van Vlierberghe, Mohamed S. Zaghloul, Marc-Eric Halatsch
Summary: This paper presents eight core attributes of cancer growth that need to be addressed for more effective treatment. It suggests that a regimen using multiple drugs will be necessary to counter the growth attributes of incurable cancer. The paper further shows how repurposed drugs can be used to block cancer cells' survival pathways and growth drives. It presents the principles of multidrug adjunctive cancer treatment (MDACT) and provides an example regimen using six repurposed drugs to interfere with common growth-driving elements in different types of cancer.
Article
Oncology
Cecilia Taverna, Abbas Agaimy, Alessandro Franchi
Summary: In recent years, molecular analysis has made significant progress in the diagnosis and treatment of sinonasal carcinomas, allowing for the classification of different subtypes and the identification of potential therapeutic targets.
Review
Pathology
Cecilia Taverna, Alessandro Franchi
Summary: Immunotherapy has shown promise in the treatment of recurrent and metastatic head and neck cancers. PD-L1 immunohistochemical expression is currently the most widely used predictive biomarker for immunotherapy in head and neck squamous cell carcinoma, but other biomarkers need to be identified for patients with PD-L1(-) tumors. This review summarizes the current data on histologic and molecular parameters for selecting patients with head and neck cancers for immunotherapy.
ADVANCES IN ANATOMIC PATHOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Eva Villanueva-Fernandez, Mario A. Hermsen, Laura Suarez-Fernandez, Blanca Vivanco, Alessandro Franchi, Rocio Garcia-Marin, Virginia N. Cabal, Helena Codina-Martinez, Sara Lucila Lorenzo-Guerra, Jose L. Llorente, Fernando Lopez
Summary: The sinonasal cavities harbor a wide variety of rare cancer types, and histopathological classification can be challenging. This study found that the presence of CD8+ tumor-infiltrating lymphocytes (TILs) and PD-L1 expression in poorly differentiated sinonasal tumors correlated with worse disease-specific survival. Thus, immunotherapy may be a promising new treatment option for this subset of patients.
Article
Pediatrics
Rossana Pavone, Carla Fonte, Iacopo Sardi, Roberto Caputo, Elisa Marziali, Fabio Mazzeo, Jacopo Secci, Alessia Bergamini, Salvatore De Masi, Maria Carmela Leo, Maria Luigia Censullo, Giacomo Maria Bacci
Summary: This study aimed to investigate the significance of optical coherence tomography (SD-OCT) in managing pediatric optic pathway gliomas (OPGs) in children younger than 5 years of age. A retrospective monocentric study was conducted, and SD-OCT scans were used to assess retinal nerve fibre layer thickness. The study confirmed the role of SD-OCT in therapeutic decisions and visual rehabilitation strategy planning for OPGs.
Review
Oncology
Juan P. Rodrigo, Mario Sanchez-Canteli, Asterios Triantafyllou, Remco de Bree, Antti A. Maekitie, Alessandro Franchi, Henrik Hellquist, Nabil F. Saba, Goeran Stenman, Robert P. Takes, Cristina Valero, Nina Zidar, Alfio Ferlito
Summary: Neutrophil-to-lymphocyte ratio (NLR) has been associated with prognosis in various cancers, including head and neck cancer. However, its prognostic value in oropharyngeal carcinomas (OPSCC), especially in relation to HPV status, is limited. This meta-analysis shows that an elevated pretreatment NLR is associated with worse outcomes in OPSCC, specifically in HPV-positive cases. NLR could serve as an affordable prognostic marker in HPV-positive OPSCC.
Article
Biochemistry & Molecular Biology
Raffaele Gaeta, Mariangela Morelli, Francesca Lessi, Chiara Maria Mazzanti, Michele Menicagli, Rodolfo Capanna, Lorenzo Andreani, Luca Coccoli, Paolo Aretini, Alessandro Franchi
Summary: This study aims to identify gene alterations in high-grade osteosarcoma (OS) patients using whole exome sequencing (WES) to find new potential prognostic biomarkers and therapeutic targets. Mutations in ARID1A, CREBBP, BRCA2 and RAD50 genes were found to be significantly correlated with poor response to neoadjuvant therapy and negatively influenced the progression-free survival time. Moreover, higher tumor mutational burden values were associated with worse prognosis.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Editorial Material
Oncology
Mario A. Hermsen, Paolo Bossi, Alessandro Franchi, Matt Lechner
Review
Oncology
Giorgia Arcovito, Annarita Palomba, Oreste Gallo, Alessandro Franchi
Summary: Laryngeal cancer, a common tumor of the head and neck, requires a combination of surgery, radiotherapy, and chemotherapy for treatment. Recurrent tumors can differ significantly from the primary tumor due to previous treatments. The immune system plays a crucial role in the disease's progression and the use of immunotherapy alongside standard treatments is becoming increasingly important. However, conventional treatments can affect the immune response, so these changes should be considered when planning immune-based treatments. This article reviews the histological and molecular changes induced by treatment that may affect the diagnosis and treatment response in recurrent laryngeal cancer patients.
Editorial Material
Oncology
Nicola Contessi Negrini, Alessandro Franchi, Serena Danti
